Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis.

Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis.

The role of antigen expression by thymomas in myasthenia gravis (MG) is not clear. Previous reports of acetylcholine receptor (AChR) mRNA expression by the highly sensitive reverse transcription-polymerase chain reactions (RT-PCR) produced varying results. To try to clarify this issue, we first used...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Maclennan, C, Vincent, A, Marx, A, Willcox, N, Gilhus, N, Newsom-Davis, J, Beeson, D
Format:	Journal article
Język:	English
Wydane:	2008

Podobne zapisy

Myasthenia gravis in a woman with congenital AChR deficiency due to epsilon-subunit mutations.
od: Croxen, R, i wsp.
Wydane: (2002)

Antibodies to AChRs in seronegative myasthenia gravis
od: Leite, M, i wsp.
Wydane: (2006)

Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures.
od: Farrugia, M, i wsp.
Wydane: (2007)

Congenital myasthenic syndrome patients due to AChR epsilon subunit mutations
od: Bonifati, D, i wsp.
Wydane: (2004)

Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
od: Mygland, A, i wsp.
Wydane: (2000)

End-plate gamma- and epsilon-subunit mRNA levels in AChR deficiency syndrome due to epsilon-subunit null mutations.
od: Croxen, R, i wsp.
Wydane: (2001)

Splice-site mutations in the achr epsilon subunit gene associated with congenital myasthenic syndrome
od: Croxen, R, i wsp.
Wydane: (2000)

Thymoma and paraneoplastic myasthenia gravis.
od: Marx, A, i wsp.
Wydane: (2010)

AChR deficiency due to epsilon-subunit mutations: two common mutations in the Netherlands.
od: Faber, C, i wsp.
Wydane: (2009)

Correlation between polymorphisms in the AChR gamma and delta subunit promoters and clinical phenotype in AChR deficiency patients
od: Bonifati, D, i wsp.
Wydane: (2004)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.
od: Vuslat Yilmaz, i wsp.
Wydane: (2015-01-01)

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis
od: Lee, J, i wsp.
Wydane: (2016)

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
od: Rui Zhao, i wsp.
Wydane: (2021-06-01)

Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis.
od: Buckley, C, i wsp.
Wydane: (2001)

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient
od: Saxena, A, i wsp.
Wydane: (2017)

Lack of association between acetylcholine receptor epsilon polymorphisms and early-onset myasthenia gravis.
od: Bonifati, D, i wsp.
Wydane: (2004)

A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis
od: Yu Cai, i wsp.
Wydane: (2021-07-01)

Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
od: Deymeer, F, i wsp.
Wydane: (2007)

The clinical outcome in AChR-positive generalized myasthenia gravis: A retrospective observational study
od: Pawan T Ojha, i wsp.
Wydane: (2023-01-01)

Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.
od: Gregory Kordas, i wsp.
Wydane: (2014-01-01)

The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey.
od: Gizem A Kaya, i wsp.
Wydane: (2014-01-01)

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
od: Antonino Lupica, i wsp.
Wydane: (2022-04-01)

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients.
od: PLOS ONE Staff
Wydane: (2015-01-01)

Correction: direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.
od: PLOS ONE Staff
Wydane: (2015-01-01)

Oral Microbiota Profile in a Group of Anti-AChR Antibody–Positive Myasthenia Gravis Patients
od: Chao Huang, i wsp.
Wydane: (2022-07-01)

A cysteine residue close to the C-terminus of the E subunit is essential for surface acetylcholine receptor (AChR) expression: Implications for AChR deficiency syndrome
od: Ealing, J, i wsp.
Wydane: (2002)

Selective silencing of pathogenic a subunit AChR mutant in dominant disorders
od: Abdelgany, A, i wsp.
Wydane: (2004)

Autoantibody of NRIP, a novel AChR‐interacting protein, plays a detrimental role in myasthenia gravis
od: Li‐Kai Tsai, i wsp.
Wydane: (2021-06-01)

Clinical outcomes in AchR antibody-positive myasthenia gravis: Where does rituximab stand in the current times?
od: Megha Chetan Dhamne
Wydane: (2023-01-01)

Mutations in congenital myasthenic syndromes reveal an epsilon subunit C-terminal cysteine, C470, crucial for maturation and surface expression of adult AChR.
od: Ealing, J, i wsp.
Wydane: (2002)

Neuromyotonia and myasthenia gravis without thymoma.
od: Van Parijs, V, i wsp.
Wydane: (2002)

Slow‐channel myasthenia due to novel mutation in M2 domain of AChR delta subunit
od: Xin‐Ming Shen, i wsp.
Wydane: (2019-10-01)

Ocular myasthenia gravis and thymoma
od: Victor Alegre-Ituarte, i wsp.
Wydane: (2022-09-01)

AChR phosphorylation and indirect inhibition of AChR function in seronegative MG.
od: Plested, C, i wsp.
Wydane: (2002)

Consensus recommendation for the treatment of generalised Myasthenia Gravis with anti-acetylcholine receptor antibodies (gMG AChR+) in Spain
od: Elena Cortés-Vicente, i wsp.
Wydane: (2025-01-01)

Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients
od: Nairong Xie, i wsp.
Wydane: (2025-01-01)

Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome.
od: Webster, R, i wsp.
Wydane: (2004)

Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
od: Eleonora Lekova, i wsp.
Wydane: (2022-09-01)

Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody
od: Yuping Chen, i wsp.
Wydane: (2022-05-01)

Structural abnormalities of the AChR caused by mutations underlying congenital myasthenic syndromes.
od: Beeson, D, i wsp.
Wydane: (2003)